Quest Diagnostics (DGX) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.35, $0.02 better than the analyst estimate of $2.33. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Quest Diagnostics sees FY2024 EPS of $8.80-$9.00, versus the consensus of $8.86.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
